Clone:
REA709
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC
Alternative names:
LRP-1, A2MR, APOER

Extended validation for CD91 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA709
A2MR-a2++
Cells were incubated with an excess of purified unconjugated CD91 (REA709) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD91. Human peripheral blood mononuclear cells (PBMCs) were stained with CD91 antibodies and with a suitable counterstaining. As a control, CD91 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD91. Human peripheral blood mononuclear cells (PBMCs) were stained with CD91 antibodies and with a suitable counterstaining. As a control, CD91 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD91. Human peripheral blood mononuclear cells (PBMCs) were stained with CD91 antibodies and with a suitable counterstaining. As a control, CD91 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD91. Human peripheral blood mononuclear cells (PBMCs) were stained with CD91 antibodies and with a suitable counterstaining. As a control, CD91 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD91 (REA709). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD91 (REA709). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD91 (REA709). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD91 Antibody, anti-human, REAfinity™

Overview

Clone REA709 recognizes the human CD91 antigen, also known as low density lipoprotein receptor-related protein 1 (LRP1), alpha-2-macroglobulin receptor (A2MR), or apolipoprotein E receptor (APOER). CD91 is a type 1 transmembrane protein receptor protein which is located in the plasma membrane of cells involved in receptor-mediated endocytosis. Furthermore, CD91 plays a role in lipoprotein metabolism and cell motility, and different diseases, such as neurodegenerative diseases, atherosclerosis, and cancer. CD91 is mainly expressed in liver, brain, and lung.
Additional information: Clone REA709 displays negligible binding to Fc receptors.

Alternative names

LRP-1, A2MR, APOER

Detailed product information

Technical specifications

CloneREA709
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD91
Alternative names of antigenLRP-1, A2MR, APOER
Molecular mass of antigen [kDa]503
Distribution of antigenlung cancer cells, brain, liver
Entrez Gene ID4035
RRIDAB_2659596, AB_2659597, AB_2659598, AB_2659599, AB_2659600, AB_2659601, AB_2659602, AB_2659603, AB_2659604, AB_2659605, AB_2659595, AB_2659594

References for CD91 Antibody, anti-human, REAfinity™

Publications

  1. Herz, J. et al. (1988) Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 7(13): 4119-4127
  2. Lillis, A.P. et al. (2005) Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J. Thromb. Haemost. 3(8): 1884-1993
  3. Etique, N. et al. (2013) LRP-1: a checkpoint for the extracellular matrix proteolysis. Biomed Res Int : 152-163

Related products for
CD91 Antibody, anti-human, REAfinity™

2 products available